Clinical Trial Update: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a minimal residual disease–driven strategy using a T-cell redirector after D-VRd therapy in newly diagnosed multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Lenalidomide (lenalidomide)
• T-cell redirector

Snippet

Sponsor: Nantes University Hospital | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING